NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
Clinical Trials
10 trialsNCT03344211 2026-02-27
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
Phase 2 Active not recruiting
NCT04489719 2026-02-17
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington
Recruiting
NCT05133440 2026-01-21
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05924672 2026-01-14
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
Phase 2 Active not recruiting
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT03361735 2025-05-02
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03304418 2025-04-30
RROPE
University of Utah
Phase 2 Completed
NCT03076203 2025-04-29
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Thomas Jefferson University
Phase 1 Completed
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting